Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Mardjuadi, A."'
Autor:
Armando Santoro, Eric Assenat, Thomas Yau, Jean-Pierre Delord, Michela Maur, Jennifer Knox, Stephane Cattan, Kyung-Hun Lee, Gianluca Del Conte, Christoph Springfeld, Elisa Leo, Alexandros Xyrafas, Lauren Fairchild, Feby Mardjuadi, Stephen L. Chan
Publikováno v:
JHEP Reports, Vol 6, Iss 4, Pp 101021- (2024)
Background & aims: This phase Ib/II trial evaluated the safety and efficacy of capmatinib in combination with spartalizumab or spartalizumab alone in patients with advanced hepatocellular carcinoma (HCC). Methods: Eligible patients who had progressed
Externí odkaz:
https://doaj.org/article/9e42ee62344d4ac28b99c8e6f48601dc
Autor:
Felip, Enriqueta, Metro, Giulio, Tan, Daniel S.W., Wolf, Juergen, Mark, Michael, Boyer, Michael, Hughes, Brett G.M., Bearz, Alessandra, Moro-Sibilot, Denis, Le, Xiuning, Puente, Javier, Massuti, Bartomeu, Tiedt, Ralph, Wang, Yingying, Xu, Chao, Mardjuadi, Feby I., Cobo, Manuel
Publikováno v:
In Lung Cancer June 2024 192
Autor:
Santoro, Armando, Assenat, Eric, Yau, Thomas, Delord, Jean-Pierre, Maur, Michela, Knox, Jennifer, Cattan, Stephane, Lee, Kyung-Hun, Del Conte, Gianluca, Springfeld, Christoph, Leo, Elisa, Xyrafas, Alexandros, Fairchild, Lauren, Mardjuadi, Feby, Chan, Stephen L.
Publikováno v:
In JHEP Reports April 2024 6(4)
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J. Wolf, R. Heist, T.M. Kim, M. Nishio, C. Dooms, R.R. Kanthala, E. Leo, E. Giorgetti, Y. Wang, F.I. Mardjuadi, A. Cortot
Publikováno v:
Annals of Oncology. 33:S1007-S1008
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b51814b64908fe69f112cf9a6a167704
https://doi.org/10.1016/j.annonc.2022.07.1120
https://doi.org/10.1016/j.annonc.2022.07.1120
Autor:
Tony S. K. Mok, Diego Luigi Cortinovis, Margarita Majem, Melissa Lynne Johnson, Feby Ingriani Mardjuadi, Xuan Zhao, Sagar Vidya Siripurapu, Zhiqiang Jiang, Juergen Wolf
Publikováno v:
Journal of Clinical Oncology. 40:9118-9118
9118 Background: Capmatinib is a selective MET inhibitor approved for patients (pts) with metastatic NSCLC harboring MET exon 14 skipping mutation. Pembrolizumab (pembro) is a programmed death protein-1 (PD-1) inhibitor approved as monotherapy for pt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f9e741db56349bca1e8ebe334125933
https://doi.org/10.1200/jco.2022.40.16_suppl.9118
https://doi.org/10.1200/jco.2022.40.16_suppl.9118
Autor:
Wolf, J., Heist, R., Kim, T.M., Nishio, M., Dooms, C., Kanthala, R.R., Leo, E., Giorgetti, E., Wang, Y., Mardjuadi, F.I., Cortot, A.
Publikováno v:
In Annals of Oncology September 2022 33 Supplement 7:S1007-S1008
Autor:
Amy V. Kapp, Stephanie Royer-Joo, Lori J. Wirth, Antonio Jimeno, X. Wang, Tanguy Y. Seiwert, Jean-Pascal Machiels, Bruce McCall, Pol Specenier, Feby Mardjuadi, Elicia Penuel, Paul Clement, Andrea Pirzkall
Publikováno v:
Cancer. 122:3803-3811
BACKGROUND This open-label, multicenter, phase Ib study assessed the safety and preliminary activity of duligotuzumab, a dual-action antibody that blocks ligand binding to human epidermal growth factor receptor 3 (HER3) and epidermal growth factor re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97ef0b534bb09f451e0370104e1f425f
https://doi.org/10.1002/cncr.30256
https://doi.org/10.1002/cncr.30256
Autor:
Antonio, Jimeno, Jean-Pascal, Machiels, Lori, Wirth, Pol, Specenier, Tanguy Y, Seiwert, Feby, Mardjuadi, Xiaodong, Wang, Amy V, Kapp, Stephanie, Royer-Joo, Elicia, Penuel, Bruce, McCall, Andrea, Pirzkall, Paul M, Clement
Publikováno v:
Cancer. 122(24)
This open-label, multicenter, phase Ib study assessed the safety and preliminary activity of duligotuzumab, a dual-action antibody that blocks ligand binding to human epidermal growth factor receptor 3 (HER3) and epidermal growth factor receptor, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bf75c3f689378466b003745b4f5d9ece
https://pubmed.ncbi.nlm.nih.gov/27525588
https://pubmed.ncbi.nlm.nih.gov/27525588
Autor:
Jimeno, Antonio, Machiels, Jean-Pascal, Wirth, Lori, Specenier, Pol, Seiwert, Tanguy Y., Mardjuadi, Feby, Wang, Xiaodong, Kapp, Amy V., Royer-Joo, Stephanie, Penuel, Elicia, McCall, Bruce, Pirzkall, Andrea, Clement, Paul M.
Publikováno v:
Cancer: interdisciplinary international journal of the American Cancer Society
BACKGROUND: This open-label, multicenter, phase Ib study assessed the safety and preliminary activity of duligotuzumab, a dualaction antibody that blocks ligand binding to human epidermal growth factor receptor 3 (HER3) and epidermal growth factor re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2097::9a5a80ba32de662841469498f1713ed3
https://hdl.handle.net/10067/1415200151162165141
https://hdl.handle.net/10067/1415200151162165141